糖尿病黄斑浮腫(DME)の世界市場

Future Market Insightsが発行した調査報告書(FUMI709082)
◆英語タイトル:Diabetic Macular Edema Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027
◆商品コード:FUMI709082
◆発行会社(リサーチ会社):Future Market Insights
◆発行日:2017年7月26日
◆ページ数:174
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Individual PriceUSD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
Corporate PriceUSD7,500 ⇒換算¥847,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はFuture Market Insights社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Future Market Insights社の概要及び新刊レポートはこちらでご確認いただけます。

Future Market Insightsが発行した本調査レポートでは、糖尿病黄斑浮腫(DME)の世界市場について調査・分析し、糖尿病黄斑浮腫(DME)の世界市場動向、糖尿病黄斑浮腫(DME)の世界市場規模、市場予測、セグメント別糖尿病黄斑浮腫(DME)市場分析、地域別市場規模(北米市場、南米市場、アジア市場、日本市場、ヨーロッパ市場など)、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

Future Market Insights forecasts the global diabetic macular edema market to grow from nearly US$ 3,710 Mn in 2017 to over US$ 4,100 Mn by 2027 end. This represents a CAGR of 1.1% over the forecast period of 2017– 2027. North America is projected to be the largest market in terms of value and accounted for the highest revenue share of 51.5% in 2016.
Growing adoption of recently approved Intravitreal implants in North America

Before the launch of Lucentis for DME treatment in 2012, the use of intravitreally injected medications was less common in North America and laser photocoagulation was the primary treatment. However, Avastin and Macugen were being used off-label for diabetic macular edema treatment since 2004. Launch of three new products in 2014 viz. Eylea, Ozurdex and Iluvien, has led to the increased adoption of Intravitreal medications in North America. For instance, according to estimates of the University of Washington, before 2004, 5.75% of DME patients used Intravitreal injections, which increased to 20% by 2013. In 2016, over 70% of DME patients were utilising Intravitreal injections and implants. This sudden increase in the adoption of Intravitreal therapies can be attributed to the launch of low dose high efficacy corticosteroid implants for Intravitreal use. Uptake of Intravitreal implants by new patients as well as by patients previously treated with Intravitreal injections but who do not show any improvement, is expected to push the market for diabetic macular edema in the region.

Growing economic burden of diabetes and related disorders

Diabetic Macular Edema (DME) is a leading cause of blindness among the working age population in most developed countries. DME is one of the major complications of diabetes and DME patients utilise significantly higher healthcare resources than non-DME diabetic patients. As per a survey conducted by the University of Washington, the total yearly median cost for DME patients was reported to be US$ 14,678 and that for non-DME diabetic patients was US$ 6,801 in 2011. Moreover, DME patients have to visit their physicians for at least 30 days per year in contrast to an average of 14 visits per year in the case of non-DME diabetic patients. The growing incidences of diabetes across the globe further increase the burden of DME. According to the International Diabetic Federation (IDF), 382 Mn people worldwide have diabetes and the number is expected to grow to 592 Mn by 2035.

Gaps in making DME a health priority hampering market growth in North America

Although control of diabetes is made a health priority in developed countries such as the U.S., much attention is not given to DME management and diabetes related caregivers tend to focus on the treatment of other diabetic complications. The major reason for this is the lack of effective treatment for DME. Even though anti-VEGF and corticosteroid therapies have changed the treatment paradigm, there exists a gap in patients’ clinical information among clinicians. Furthermore, there exists an error in industry sponsored and independently run clinical trials. For instance, there are approximately 72 independent clinical trials going on for DME treatment, but most of them lack long-term results regarding safety and efficacy on new and combination therapies for diabetic macular edema. These factors are hampering revenue growth of the diabetic macular edema market in North America. Western Europe is expected to be the most lucrative market for diabetic macular edema, with market attractiveness index of 2.7. Major players in the diabetic macular edema market, including Bayer AG and Novartis AG, are focussing on improving the sale of Eylea and Lucentis, respectively, in Europe. Companies are trying to exploit the full market potential and get maximum returns on R&D till patents for their drugs are alive. North America dominated the diabetic macular edema market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. North America is expected to be the second most lucrative among all regions, with an attractiveness index of 2.5. APEJ represents the third largest market with a market attractiveness index of 0.4. MEA is expected to remain the least attractive regional market for diabetic macular edema in revenue terms, with an attractiveness index of 0.1 over the forecast period.

【レポートの目次】

Table Of Content
1. Executive Summary

1.1. Market Overview

1.2. Market Analysis

1.3. FMI Analysis and Recommendations

1.4. Wheel of Fortune

2. Market Introduction

2.1. Market Taxonomy

2.2. Market Definition

3. Diabetic Macular Edema Market View Point

3.1. Macro-Economic Factors

3.2. Opportunity Analysis

3.3. Pipeline Analysis

3.4. Disease Epidemiology

4. North America Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027

4.1. Introduction

4.2. Regional Market Dynamics

4.2.1. Drivers

4.2.2. Restraints

4.2.3. Trends

4.3. Historical Market Size (US$ Mn) By Country, 2012-2016

4.3.1. U.S.

4.3.2. Canada

4.4. Market Size (US$ Mn) Forecast By Country, 2017-2027

4.4.1. U.S.

4.4.2. Canada

4.5. Historical Market Size (US$ Mn) By Product Type, 2012-2016

4.5.1. Anti VEGF Therapies

4.5.1.1. Ranibizumab (Lucentis)

4.5.1.2. Afilbercept (Eylea)

4.5.2. Corticosteroid Therapies

4.5.2.1. Dexamethasone (Ozurdex)

4.5.2.2. Fluocinolone Acetonide (Iluvien)

4.5.3. Other Off-label Drugs

4.6. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

4.6.1. Anti VEGF Therapies

4.6.1.1. Ranibizumab (Lucentis)

4.6.1.2. Afilbercept (Eylea)

4.6.2. Corticosteroid Therapies

4.6.2.1. Dexamethasone (Ozurdex)

4.6.2.2. Fluocinolone Acetonide (Iluvien)

4.6.3. Other Off-label Drugs

4.7. Historical Market Size (US$ Mn) By Product Form, 2012-2016

4.7.1. Intravitreal Injections

4.7.2. Intravitreal Implants

4.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

4.8.1. Intravitreal Injections

4.8.2. Intravitreal Implants

4.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

4.9.1. Retail Pharmacies

4.9.2. Hospital Pharmacies

4.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

4.10.1. Retail Pharmacies

4.10.2. Hospital Pharmacies

4.11. Market Attractiveness Analysis

4.11.1. By Country

4.11.2. By Product Type

4.11.3. By Product Form

4.11.4. By Distribution Channel

5. Western Europe Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027

5.1. Introduction

5.2. Regional Market Dynamics

5.2.1. Drivers

5.2.2. Restraints

5.2.3. Trends

5.3. Historical Market Size (US$ Mn) By Country, 2012-2016

5.3.1. Germany

5.3.2. U.K

5.3.3. France

5.3.4. Italy

5.3.5. Spain

5.3.6. Rest of Western Europe

5.4. Market Size (US$ Mn) Forecast By Country, 2017-2027

5.4.1. Germany

5.4.2. U.K

5.4.3. France

5.4.4. Italy

5.4.5. Spain

5.4.6. Rest of Western Europe

5.5. Historical Market Size (US$ Mn) By Product Type, 2012-2016

5.5.1. Anti VEGF Therapies

5.5.1.1. Ranibizumab (Lucentis)

5.5.1.2. Afilbercept (Eylea)

5.5.2. Corticosteroid Therapies

5.5.2.1. Dexamethasone (Ozurdex)

5.5.2.2. Fluocinolone Acetonide (Iluvien)

5.5.3. Other Off-label Drugs

5.6. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

5.6.1. Anti VEGF Therapies

5.6.1.1. Ranibizumab (Lucentis)

5.6.1.2. Afilbercept (Eylea)

5.6.2. Corticosteroid Therapies

5.6.2.1. Dexamethasone (Ozurdex)

5.6.2.2. Fluocinolone Acetonide (Iluvien)

5.6.3. Other Off-label Drugs

5.7. Historical Market Size (US$ Mn) By Product Form, 2012-2016

5.7.1. Intravitreal Injections

5.7.2. Intravitreal Implants

5.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

5.8.1. Intravitreal Injections

5.8.2. Intravitreal Implants

5.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

5.9.1. Retail Pharmacies

5.9.2. Hospital Pharmacies

5.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

5.10.1. Retail Pharmacies

5.10.2. Hospital Pharmacies

5.11. Market Attractiveness Analysis

5.11.1. By Country

5.11.2. By Product Type

5.11.3. By Product Form

5.11.4. By Distribution Channel

6. Eastern Europe Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027

6.1. Introduction

6.2. Regional Market Dynamics

6.2.1. Drivers

6.2.2. Restraints

6.2.3. Trends

6.3. Historical Market Size (US$ Mn) By Country, 2012-2016

6.3.1. Russia

6.3.2. Poland

6.3.3. Rest of Eastern Europe

6.4. Market Size (US$ Mn) Forecast By Country, 2017-2027

6.4.1. Russia

6.4.2. Poland

6.4.3. Rest of Eastern Europe

6.5. Historical Market Size (US$ Mn) By Product Type, 2012-2016

6.5.1. Anti VEGF Therapies

6.5.1.1. Ranibizumab (Lucentis)

6.5.1.2. Afilbercept (Eylea)

6.5.2. Corticosteroid Therapies

6.5.2.1. Dexamethasone (Ozurdex)

6.5.2.2. Fluocinolone Acetonide (Iluvien)

6.5.3. Other Off-label Drugs

6.6. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

6.6.1. Anti VEGF Therapies

6.6.1.1. Ranibizumab (Lucentis)

6.6.1.2. Afilbercept (Eylea)

6.6.2. Corticosteroid Therapies

6.6.2.1. Dexamethasone (Ozurdex)

6.6.2.2. Fluocinolone Acetonide (Iluvien)

6.6.3. Other Off-label Drugs

6.7. Historical Market Size (US$ Mn) By Product Form, 2012-2016

6.7.1. Intravitreal Injections

6.7.2. Intravitreal Implants

6.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

6.8.1. Intravitreal Injections

6.8.2. Intravitreal Implants

6.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

6.9.1. Retail Pharmacies

6.9.2. Hospital Pharmacies

6.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

6.10.1. Retail Pharmacies

6.10.2. Hospital Pharmacies

6.11. Market Attractiveness Analysis

6.11.1. By Country

6.11.2. By Product Type

6.11.3. By Product Form

6.11.4. By Distribution Channel

7. Latin America Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027

7.1. Introduction

7.2. Key Regulations

7.3. Regional Market Dynamics

7.3.1. Drivers

7.3.2. Restraints

7.3.3. Trends

7.4. Historical Market Size (US$ Mn) By Country, 2012-2016

7.4.1. Brazil

7.4.2. Mexico

7.4.3. Rest of Latin America

7.5. Market Size (US$ Mn) Forecast By Country, 2017-2027

7.5.1. Brazil

7.5.2. Mexico

7.5.3. Rest of Latin America

7.6. Historical Market Size (US$ Mn) By Product Type, 2012-2016

7.6.1. Anti VEGF Therapies

7.6.1.1. Ranibizumab (Lucentis)

7.6.1.2. Afilbercept (Eylea)

7.6.2. Corticosteroid Therapies

7.6.2.1. Dexamethasone (Ozurdex)

7.6.2.2. Fluocinolone Acetonide (Iluvien)

7.6.3. Other Off-label Drugs

7.7. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

7.7.1. Anti VEGF Therapies

7.7.1.1. Ranibizumab (Lucentis)

7.7.1.2. Afilbercept (Eylea)

7.7.2. Corticosteroid Therapies

7.7.2.1. Dexamethasone (Ozurdex)

7.7.2.2. Fluocinolone Acetonide (Iluvien)

7.7.3. Other Off-label Drugs

7.8. Historical Market Size (US$ Mn) By Product Form, 2012-2016

7.8.1. Intravitreal Injections

7.8.2. Intravitreal Implants

7.9. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

7.9.1. Intravitreal Injections

7.9.2. Intravitreal Implants

7.10. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

7.10.1. Retail Pharmacies

7.10.2. Hospital Pharmacies

7.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

7.11.1. Retail Pharmacies

7.11.2. Hospital Pharmacies

7.12. Market Attractiveness Analysis

7.12.1. By Country

7.12.2. By Product Type

7.12.3. By Product Form

7.12.4. By Distribution Channel

7.13. Key Representative Market Participants

7.14. Key Participants Market Presence (Intensity Map)

8. Asia Pacific Excluding Japan Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027

8.1. Introduction

8.2. Regional Market Dynamics

8.2.1. Drivers

8.2.2. Restraints

8.2.3. Trends

8.3. Historical Market Size (US$ Mn) By Country, 2012-2016

8.3.1. China

8.3.2. India

8.3.3. Australia and New Zealand

8.3.4. ASEAN

8.3.5. Rest of APEJ

8.4. Market Size (US$ Mn) Forecast By Country, 2017-2027

8.4.1. China

8.4.2. India

8.4.3. Australia and New Zealand

8.4.4. ASEAN

8.4.5. Rest of APEJ

8.5. Historical Market Size (US$ Mn) By Product Type, 2012-2016

8.5.1. Anti VEGF Therapies

8.5.1.1. Ranibizumab (Lucentis)

8.5.1.2. Afilbercept (Eylea)

8.5.2. Corticosteroid Therapies

8.5.2.1. Dexamethasone (Ozurdex)

8.5.2.2. Fluocinolone Acetonide (Iluvien)

8.5.3. Other Off-label Drugs

8.6. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

8.6.1. Anti VEGF Therapies

8.6.1.1. Ranibizumab (Lucentis)

8.6.1.2. Afilbercept (Eylea)

8.6.2. Corticosteroid Therapies

8.6.2.1. Dexamethasone (Ozurdex)

8.6.2.2. Fluocinolone Acetonide (Iluvien)

8.6.3. Other Off-label Drugs

8.7. Historical Market Size (US$ Mn) By Product Form, 2012-2016

8.7.1. Intravitreal Injections

8.7.2. Intravitreal Implants

8.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

8.8.1. Intravitreal Injections

8.8.2. Intravitreal Implants

8.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

8.9.1. Retail Pharmacies

8.9.2. Hospital Pharmacies

8.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

8.10.1. Retail Pharmacies

8.10.2. Hospital Pharmacies

8.11. Market Attractiveness Analysis

8.11.1. By Country

8.11.2. By Product Type

8.11.3. By Product Form

8.11.4. By Distribution Channel

9. Japan Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027

9.1. Introduction

9.2. Regional Market Dynamics

9.2.1. Drivers

9.2.2. Restraints

9.2.3. Trends

9.3. Historical Market Size (US$ Mn) By Product Type, 2012-2016

9.3.1. Anti VEGF Therapies

9.3.1.1. Ranibizumab (Lucentis)

9.3.1.2. Afilbercept (Eylea)

9.3.2. Corticosteroid Therapies

9.3.2.1. Dexamethasone (Ozurdex)

9.3.2.2. Fluocinolone Acetonide (Iluvien)

9.3.3. Other Off-label Drugs

9.4. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

9.4.1. Anti VEGF Therapies

9.4.1.1. Ranibizumab (Lucentis)

9.4.1.2. Afilbercept (Eylea)

9.4.2. Corticosteroid Therapies

9.4.2.1. Dexamethasone (Ozurdex)

9.4.2.2. Fluocinolone Acetonide (Iluvien)

9.4.3. Other Off-label Drugs

9.5. Historical Market Size (US$ Mn) By Product Form, 2012-2016

9.5.1. Intravitreal Injections

9.5.2. Intravitreal Implants

9.6. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

9.6.1. Intravitreal Injections

9.6.2. Intravitreal Implants

9.7. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

9.7.1. Retail Pharmacies

9.7.2. Hospital Pharmacies

9.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

9.8.1. Retail Pharmacies

9.8.2. Hospital Pharmacies

9.9. Market Attractiveness Analysis

9.9.1. By Product Type

9.9.2. By Product Form

9.9.3. By Distribution Channel

10. Middle East and Africa Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027

10.1. Introduction

10.2. Regional Market Dynamics

10.2.1. Drivers

10.2.2. Restraints

10.2.3. Trends

10.3. Historical Market Size (US$ Mn) By Country, 2012-2016

10.3.1. GCC Countries

10.3.2. South Africa

10.3.3. Rest of Middle East and Africa

10.4. Market Size (US$ Mn) Forecast By Country, 2017-2027

10.4.1. GCC Countries

10.4.2. South Africa

10.4.3. Rest of Middle East and Africa

10.5. Historical Market Size (US$ Mn) By Product Type, 2012-2016

10.5.1. Anti VEGF Therapies

10.5.1.1. Ranibizumab (Lucentis)

10.5.1.2. Afilbercept (Eylea)

10.5.2. Corticosteroid Therapies

10.5.2.1. Dexamethasone (Ozurdex)

10.5.2.2. Fluocinolone Acetonide (Iluvien)

10.5.3. Other Off-label Drugs

10.6. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

10.6.1. Anti VEGF Therapies

10.6.1.1. Ranibizumab (Lucentis)

10.6.1.2. Afilbercept (Eylea)

10.6.2. Corticosteroid Therapies

10.6.2.1. Dexamethasone (Ozurdex)

10.6.2.2. Fluocinolone Acetonide (Iluvien)

10.6.3. Other Off-label Drugs

10.7. Historical Market Size (US$ Mn) By Product Form, 2012-2016

10.7.1. Intravitreal Injections

10.7.2. Intravitreal Implants

10.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

10.8.1. Intravitreal Injections

10.8.2. Intravitreal Implants

10.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

10.9.1. Retail Pharmacies

10.9.2. Hospital Pharmacies

10.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

10.10.1. Retail Pharmacies

10.10.2. Hospital Pharmacies

10.11. Market Attractiveness Analysis

10.11.1. By Country

10.11.2. By Product Type

10.11.3. By Product Form

10.11.4. By Distribution Channel

10.12. Key Representative Market Participants

10.13. Key Participants Market Presence (Intensity Map)

11. Forecast Factors: Relevance and Impact

12. Forecast Assumptions

13. Competition Landscape

13.1. Market Structure

13.2. Competition Intensity Mapping By Market Taxonomy

13.3. Competition Dashboard

13.4. Key Participants Market Presence (Intensity Map)

13.5. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

13.5.1. Novartis AG

13.5.2. Bayer AG

13.5.3. Allergan Plc.

13.5.4. F. Hoffman-La Roche Ltd.

13.5.5. Alimera Sciences Inc.

13.5.6. Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.)

14. Global Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027 By Region

14.1. Introduction / Key Findings

14.2. Historical Market Size (US$ Mn) By Region

14.2.1. North America

14.2.2. Western Europe

14.2.3. Eastern Europe

14.2.4. Latin America

14.2.5. Asia Pacific Excluding Japan

14.2.6. Japan

14.2.7. Middle East and Africa

14.3. Market Size (US$ Mn) Forecast By Region

14.3.1. North America

14.3.2. Western Europe

14.3.3. Eastern Europe

14.3.4. Latin America

14.3.5. Asia Pacific Excluding Japan

14.3.6. Japan

14.3.7. Middle East and Africa

14.4. Market Attractiveness Analysis By Region

15. Global Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027, By Product Type

15.1. Introduction/Key Finding

15.2. Historical Market Size (US$ Mn) By Product Type, 2012-2016

15.2.1. Anti VEGF Therapies

15.2.1.1. Ranibizumab (Lucentis)

15.2.1.2. Afilbercept (Eylea)

15.2.2. Corticosteroid Therapies

15.2.2.1. Dexamethasone (Ozurdex)

15.2.2.2. Fluocinolone Acetonide (Iluvien)

15.2.3. Other Off-label Drugs

15.3. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

15.3.1. Anti VEGF Therapies

15.3.1.1. Ranibizumab (Lucentis)

15.3.1.2. Afilbercept (Eylea)

15.3.2. Corticosteroid Therapies

15.3.2.1. Dexamethasone (Ozurdex)

15.3.2.2. Fluocinolone Acetonide (Iluvien)

15.3.3. Other Off-label Drugs

15.4. Key Trends / Developments

15.5. Market Attractiveness Analysis By Product Type

16. Global Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027, By Product Form

16.1. Introduction/Key Finding

16.2. Historical Market Size (US$ Mn) By Product Form, 2012-2016

16.2.1. Intravitreal Injections

16.2.2. Intravitreal Implants

16.3. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

16.3.1. Intravitreal Injections

16.3.2. Intravitreal Implants

16.4. Market Attractiveness Analysis By Distribution Channel

17. Global Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027, By Distribution Channel

17.1. Introduction/Key Finding

17.2. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

17.2.1. Retail Pharmacies

17.2.2. Hospital Pharmacies

17.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

17.3.1. Retail Pharmacies

17.3.2. Hospital Pharmacies

17.4. Market Attractiveness Analysis By Distribution Channel

18. Global Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027

18.1. Market Size and Y-o-Y Growth

18.2. Absolute $ Opportunity

18.3. Value Chain



【レポートのキーワード】

糖尿病黄斑浮腫(DME)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 糖尿病黄斑浮腫(DME)の世界市場(Diabetic Macular Edema Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆